ASH 2016 | Ibrutinib updates from ASH 2016

Peter Hillmen

Peter Hillmen, MBChb, PhD, FRCP, FRCPath of St. James’ University Hospital, Leeds, UK discusses the update on ibrutinib for chronic lymphocytic leukemia (CLL) presented at the 2016 Annual Meeting of the American Society of Hematology, held in San Diego, CA. The RESONATE-2 trial looked at frontline ibrutinib compared with chlorambucil (NCT01722487). Prof. Hillmen explains that the updated data are looking very positive with patients randomized to ibrutinib having good progression-free survival (PFS). Further, the five-year update of a small Phase II trial of single agent ibrutinib also shows durable remissions (NCT01105247).

Share this video